Wyeth Articles
NKRF kick-starts UK renal patient network
30 May 2005
Diet drug trial finishes first phase
30 May 2005
Judge overturns Wyeth verdict
23 May 2005
Stock Commentary - New York
28 April 2005
Contraceptive sponge returns to US market
27 April 2005
EMEA warning over SSRIs, SNRIs in children
26 April 2005
Wyeth 1st-qtr earnings rocket 44%
25 April 2005
Wyeth wins further diet drug cases
18 April 2005
Wyeth to take full control of Takeda JV
11 April 2005
Japan stock market week to April 4
11 April 2005
Stock Commentary - New York
4 April 2005
UK guide for industry on Rx access in DCs
4 April 2005
Wyeth reaffirms 1st qtr EPS guidance
4 April 2005
Curis gets milestone from Wyeth alliance
28 March 2005
Editor's views on DTC advertising
28 March 2005
ViroPharma drops hepatitis C candidate
21 March 2005
Sanofi-Aventis to boost vaccines investment
14 March 2005
Wyeth continues vaccine alliance with Ambion Diagnostics
14 March 2005
Progress in settling Wyeth diet drug claims
7 March 2005
Solvay sees dip in 2004 pharma sales
7 March 2005
Wyeth wins PA diet drug trial
7 March 2005
New US ethnic pharma marketing research
28 February 2005
Enbrel improves psoriasis symptoms, study confirms
28 February 2005
Abbot's Humira gives promising psoriasis results
28 February 2005
Japan stock market week to February 21
28 February 2005
ViroPharma initiates Hep C drug trial
21 February 2005
ImClone recruits Philip Frost and Eric Rowinsky to executive posts
21 February 2005
Wyeth named to R&D "pipelineline to watch"
21 February 2005
Wyeth promotes James Pohlman to VP, corporate strategic initiatives.
14 February 2005
Stock Commentary - New York
14 February 2005
Stock Commentary - New York
7 February 2005
Wyeth adds 52 new biotech jobs in Massachusetts
7 February 2005
Japan stock market week to January 31
7 February 2005
Fen-phem charges gouge Wyeth results
7 February 2005
Stock Commentary - New York
31 January 2005
Enbrel approved for RA in Japan
31 January 2005
Wyeth prevails in Natural Biologics case
31 January 2005
Wyeth nearing diet drug settlement?
31 January 2005
Stock Commentary - New York
24 January 2005
ArQule achieves two milestones under Wyeth deal
17 January 2005
Genzyme completes buyback of Synvisc
17 January 2005
Wyeth to support diet drug amendment
17 January 2005
Preclinical program for RhuDex nearing completion
10 January 2005
Wyeth wins one of two PA diet drug cases
10 January 2005
Wyeth looking for global approval of Tygacil
20 December 2004
Pharmaceutical firms are conducting trials oversees
20 December 2004
Stock Commentary - New York
13 December 2004
UK MHRA calls for curbs on SSRIs; Wyeth to challenge Efexor cautions
13 December 2004
Epigenomics 3rd-qtr sales beat targets
15 November 2004
Wyeth and Plexxikon sign diabetes deal
8 November 2004
MedImmune's 3rd-qtr loss grows four-fold
1 November 2004
US uninsured "pay 78% more than best Rx prices"
1 November 2004
New data for Amgen/Wyeth's Enbrel at ACR
25 October 2004
Karo Bio narrows loss for 3rd-qtr 2004
25 October 2004
Richard Lyttle joins Nuvios as president and chief executive
11 October 2004
Wyeth announces promotions
11 October 2004
Enbrel cleared for psoriasis in EU
11 October 2004
Expanded US label for Amgen/Wyeth's Enbrel
4 October 2004
Genentech and Wyeth in manufacturing accord
4 October 2004
Elan and Wyeth obtain patents for AD therapies
27 September 2004
Wyeth discontinues operations at West Chester
20 September 2004
Dharmacon expands RNAi deal with Wyeth
13 September 2004
Former Aventis exec Thomas Hofstaetter joins Wyeth
13 September 2004
Pfizer limits Rx supplies to UK wholesalers
13 September 2004
Lehman initiates coverage of Epigenomics with overweight rating
13 September 2004
Epigenomics is at the
6 September 2004
US judge OKs changes for fen-phen claims
6 September 2004
Wyeth oncology researchers honored
30 August 2004
Wyeth's temsirolimus on FDA fast-track
23 August 2004
Wyeth wins multiple Philadelpha diet drug cases
23 August 2004
Vice presidents named at Wyeth
16 August 2004
French drug evaluation group starts work
16 August 2004
Altana beats forecasts with 7% profit rise
9 August 2004
CHMP recommends Enbrel for psoriasis
9 August 2004
MedImmune's 2nd-qtr plunges into loss
2 August 2004
Fen-Phen Trust solution approved
2 August 2004
Wyeth's 2nd-qtr profit slips, but sales climb
26 July 2004
Scotland backs Enbrel in psoriatic arthritis
26 July 2004
Karo Bio's sales slide 72% in 2nd-qtr 2004
19 July 2004
Able gains FDA appro for generic promethazine
12 July 2004
PhRMA agenda "must be about helping people"
5 July 2004
- US Supreme Court says patent settlement can "sometimes" be illegal
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
